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ReseaRch BRief
aBstRact A major obstacle to curing chronic myeloid leukemia (CML) is residual disease main-
tained by tyrosine kinase inhibitor (TKI)–persistent leukemic stem cells (LSC). These 
are BCR–ABL1 kinase independent, refractory to apoptosis, and serve as a reservoir to drive relapse or 
TKI resistance. We demonstrate that Polycomb Repressive Complex 2 is misregulated in chronic phase 
CML LSCs. This is associated with extensive reprogramming of H3K27me3 targets in LSCs, thus sensi-
tizing them to apoptosis upon treatment with an EZH2-specific inhibitor (EZH2i). EZH2i does not impair 
normal hematopoietic stem cell survival. Strikingly, treatment of primary CML cells with either EZH2i 
or TKI alone caused significant upregulation of H3K27me3 targets, and combined treatment further 
potentiated these effects and resulted in significant loss of LSCs compared to TKI alone, in vitro, and 
in long-term bone marrow murine xenografts. Our findings point to a promising epigenetic-based thera-
peutic strategy to more effectively target LSCs in patients with CML receiving TKIs.
SIGNIFICANCE: In CML, TKI-persistent LSCs remain an obstacle to cure, and approaches to eradicate 
them remain a significant unmet clinical need. We demonstrate that EZH2 and H3K27me3 reprogram-
ming is important for LSC survival, but renders LSCs sensitive to the combined effects of EZH2i and 
TKI. This represents a novel approach to more effectively target LSCs in patients receiving TKI treat-
ment. Cancer Discov; 6(11); 1–10. ©2016 AACR.
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iNtRODUctiON
Chronic myeloid leukemia (CML) is a clonal hematopoi-
etic stem cell (HSC) disorder, arising through the acquisition 
and expression of the fusion BCR–ABL1 tyrosine kinase, which 
stimulates a number of key survival pathways to drive the disease. 
Despite the introduction of tyrosine kinase inhibitors (TKI), 
which have transformed the clinical course of CML from a 
fatal to a manageable disease for the vast majority of patients, 
only ∼10% of those who present in chronic phase (CP) can 
discontinue treatment and maintain a therapy-free remission 
without relapse (1). The remaining 90% of patients require 
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lifelong TKIs and can experience serious side effects, compliance 
issues, and high costs, or they develop TKI resistance (20%–30% 
of cases) and/or progress to advanced disease for which there 
are no effective drug therapies. The low cure rate in CML is 
thought to be due to a pool of TKI-persistent and BCR–ABL1 
kinase–independent (2, 3) leukemic stem cells (LSC). LSCs in 
CML are defined as Philadelphia chromosome–positive (Ph+) 
CD34+CD38− primitive progenitor cells that show a higher 
capacity to engraft in immunocompromised mice than in bulk 
CD34+ cells (4), have stem-cell properties (quiescence and self-
renewal), are prone to genomic instability (5), and are resistant 
to apoptosis (6, 7). Novel therapeutic strategies that target these 
LSCs must be developed to address an important unmet clinical 
need for the vast majority of patients currently on TKI therapy.
The epigenetic “writer” complex Polycomb Repressive Com-
plex 2 (PRC2) is fundamental for defining stem-cell identity, 
where it primarily regulates gene repression using trimethyla-
tion of lysine 27 on histone H3 (H3K27me3; ref. 8). Although 
its methyltransferase activity can be mediated by either EZH1 
or EZH2, aberrant H3K27me3 and EZH2 activity has been 
implicated in the progression or poor prognosis of solid 
tumors and hematologic malignancies (9, 10). However, little 
is known about the role of EZH2 in CML, and unlike other 
myeloid malignancies, inactivating mutations of EZH2 in 
CML are rare (11, 12), although upregulation of EZH2 can 
result in a form of myeloproliferative disease (13).
ResULts
In comparative mRNA profiling of normal and CP CML 
primary samples representative of those in our CML biobank 
(on average ≥ 95% Ph+ in CD34+ or CD34+CD38− cells; see 
Methods), we observed significant misregulation in the lev-
els of several PRC2 components—predominantly between 
CD34+CD38− HSCs and CD34+CD38− LSCs and, to a lesser 
extent, between CD34+CD38+ leukemic progenitor cells and 
normal CD34+CD38+ hematopoietic progenitor cells (LPCs 
and HPCs respectively; Fig. 1A; Supplementary Fig. S1A–S1C). 
Significant downregulation of EZH1 in LSCs was found often 
in combination with EZH2 upregulation, creating a scenario 
where the relative levels of EZH2 compared to EZH1 increased 
2- to 16-fold across the 10 CML samples we examined (Fig. 
1A). Levels of EZH2, as well as other PRC2 components, were 
significantly downregulated in LSCs treated with TKI in vitro, 
indicative of kinase-dependent regulation. The levels of EZH1, 
however, appeared kinase independent, thus maintaining an 
EZH balance favoring EZH2 in TKI-persistent cells (Supple-
mentary Fig. S2A–S2C).
To understand the molecular consequences of PRC2 mis-
regulation, we performed chromatin immunoprecipitation 
sequencing (ChIP-seq) in normal and CML primary stem 
and progenitor cell samples (a first in CML LSCs). We identi-
fied statistically significant changes in H3K27me3 levels at 
promoters in three pairwise comparisons (Fig. 1B; Supple-
mentary Fig. S3A). In total, across the three CML samples, 
changes in H3K27me3 levels were identified at 4,101 promot-
ers, 83% of which were unique to CML (Fig. 1C). A quarter of 
these were common to all three samples and consistent with 
gains or losses of EZH2 target genes (Supplementary Fig. 
S3B). A significant majority of these changes (2,978; 73%) 
occurred between the HSC and LSC, indicative of extensive 
epigenetic reprogramming in the LSC.
Although the repressive function of EZH2 and H3K27me3 
is well documented, changes in gene expression at EZH2 tar-
get genes are not always mechanistically linked to H3K27me3 
levels in normal hematopoiesis (14). We therefore asked what 
impact H3K27me3 reprogramming would have on gene 
expression in CML. Significant mRNA expression changes 
between normal and leukemic stem and progenitor cells were 
determined globally (Supplementary Fig. S4A; Supplementary 
Table S1), and from these we identified a subset of H3K27me3 
reprogrammed target genes, whose mRNAs were either upreg-
ulated or downregulated (examples shown, Fig. 1D). In agree-
ment with previous observations (14), we found no evidence 
that H3K27me3 levels were linked to changes in gene expres-
sion during normal cell fate decisions (HSC → HPC; Fig. 
1E). However, in the three CML samples, the association 
between changes in gene expression and H3K27me3 levels 
was significantly different from that predicted by H3K27me3 
reprogramming (Fig. 1E; Supplementary Fig. S4B) and indica-
tive of H3K27me3 having its canonical repressive role. This 
association was most significant in the “early” changes (HSC 
vs. LSC), particularly among promoters reprogrammed in all 
3 CML samples (common; Fig. 1F; Supplementary Fig. S4C) 
and pointed to an altered dependency between H3K27me3 
and gene expression primarily in the LSC (Fig. 1G).
Based on the epigenetic evidence, we hypothesized that EZH2 
inhibition would represent a potential novel therapeutic strat-
egy to selectively target LSCs given that HSCs require EZH1 
(14) for survival but not EZH2 (15). We therefore treated CML 
and normal primary cells in vitro with a highly specific EZH2i, 
GSK343 (ref. 16; Fig. 2A; Supplementary Fig. S5A–S5H). We 
confirmed a selective dose-dependent decrease, but not a com-
plete loss, of H3K27me3 in response to EZH2i in both CML 
and normal CD34+ cells (Fig. 2B; Supplementary Fig. S5B). 
Treatment of bulk CML CD34+ cells and LSCs with the EZH2i 
resulted in modest but significant (≈20%–40%) reductions in 
viable cells including quiescent (undivided; CTVmax staining; 
see Methods) cells (17), along with increases in apoptosis, par-
ticularly in undivided cells (Fig. 2C and D; Supplementary Figs. 
S5A, S5C, S6A–S6C). More pronounced decreases (≈60%–80%), 
however, were seen for total colony-forming cell (CFC) and 
primitive granulocyte/erythroid/macrophage/megakaryocyte 
(GEMM) outputs (Fig. 2E; Supplementary Figs. S5A, S5D, S6A, 
S6B, S6D), and for those of long-term culture-initiating cell 
(LTC-IC) assays that enrich for primitive LSCs (Fig. 2F; Supple-
mentary Fig. S5E). This suggested that the primitive stem and 
progenitor cells were being preferentially targeted by EZH2i, 
supporting our hypothesis. Similar results were seen for CML 
CD34+ cells treated with other novel EZH2i (Supplementary 
Fig. S5A). Normal CD34+ cells treated with EZH2i were spared 
from the deleterious effects seen in CML cells (Fig. 2C–F; Sup-
plementary Fig. S5F–S5H), thus demonstrating a potential 
therapeutic window for EZH2i in CML. We observed similar 
results using shRNAs against EZH2 in a CML cell line (Supple-
mentary Fig. S7A–S7C) and in CML CD34+ cells (Fig. 2G). On-
target effects were confirmed by global mRNA analysis, where 
CML and normal CD34+ cells treated with EZH2i both showed 
significant overrepresentation of upregulated H3K27me3 tar-
gets (Fig. 2H; Supplementary Fig. S8A, S8B; Supplementary 
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figure 1.  Misregulation of PRC2 leads to H3K27me3 reprogramming and increased coupling of H3K27me3 and mRNA expression in CML LSCs. A (top),  
the mean fold changes in mRNA expression for 6 PRC2 components and BCR–ABL1 in normal (HSCs and HPCs) and CML (LSCs and LPCs) cells as 
determined by Fluidigm analysis performed in triplicate. Fold changes (log2) are expressed relative to levels found in HSCs. Error bars are standard error 
measurements (SEM). Bottom, the mean levels of EZH2 mRNA relative to EZH1 mRNA in each of the bioreplicate samples as above. Significant P values 
(*; Student t test) between equivalent cell type comparisons (HSC vs. LSC, HPC vs. LPC) are shown. Bioreplicates are n = 4 (HPC), n = 3 (HSC), n = 10 (LSC), 
and n = 10 (LPC). B, schematic diagram depicts how changes in H3K27me3 levels between normal and CML cells were determined with respect to three 
pairwise cell-type comparisons: HSCs vs. HPCs (“norm”), HSCs vs. LSCs (“early”), LSCs vs. LPCs (“late”). C, Venn diagram depicts the relationship between 
the numbers of promoters that show altered levels of H3K27me3 in three pairwise comparisons (HSC→HPC; HSC→LSC; LSC→LPC).D, examples of 
H3K27me3 read densities across genes that are upregulated (red arrow) or downregulated (green arrow; mRNA) in CML cells compared to HSCs. Loca-
tion of transcription start site and direction of transcription are shown by →. Profiles were visualized in the UCSC genome browser (hg18; NCBI build 
36.1). E, bar diagrams show the percentages (%) of all reprogrammed promoters having significant gains (red) or losses (green) of H3K27me3 (P < 0.05; 
one-sample t tests) when their cognate mRNA levels are downregulated (↓) or upregulated (↑; Affymetrix analysis) in each of three pairwise comparisons 
for 3 bioreplicate CML(1,2,3) and normal samples. F, bar diagrams show the percentages (%) of all promoters reprogrammed in all three CML samples 
(common) having significant gains (red) or losses (green) of H3K27me3 (P < 0.05; one-sample t tests) when their cognate mRNA levels are downregu-
lated (↓) or upregulated (↑; Affymetrix analysis) as above. In E and F, expected percentages of H3K27me3 gains associated with global reprogramming 
of H3K27me3 levels, irrespective of mRNA expression changes, are shown (white bars). Significant P values (*) shown are based on observed versus 
expected levels of H3K27me3 gains or losses at promoters (Yates χ2 or Fisher exact tests). G, schematic representation of H3K27me3 reprogramming 
in CML leading to increased mechanistic coupling of H3K27me3 levels and mRNA expression, consistent with an altered dependency for EZH2 in CML 
(upward green arrow). HSCs require EZH1(14) but not EZH2(15) (downward green arrow).
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Table S2). However, relatively few EZH2i-deregulated targets 
were in common between CML and normal cells, and only CML 
cells showed significant upregulation of apoptotic pathways 
(Fig. 2I; Supplementary Table S3). This provides further mecha-
nistic support that global epigenetic reprogramming results in 
an altered dependency on EZH2 and H3K27me3 in CML cells, 
and this sensitizes LSCs, but not HSCs, to EZH2 inhibition.
An important area of unmet clinical need in CML is the 
eradication of a subpopulation of LSCs that are refractory to 
TKI treatment (18, 19). By analyzing global datasets of CML 
CD34+ cells or LSCs treated with EZH2i or TKI and by using 
an additive model for combined drug effects, we predicted 
that a combination of EZH2i and TKI would be more effective 
at upregulating H3K27me3 target genes than EZH2i alone 
(Supplementary Figs. S9A–S9D, S10A–S10D). This was, in 
part, attributable to TKI treatment alone resulting in substan-
tial upregulation of H3K27me3 targets (Fig. 3A). However, we 
found little evidence that TKI or EZH2i returned mRNA levels 
of H3K27me3 targets to those found in normal stem or pro-
genitor cells (Supplementary Figs. S11A–S11C, S12).
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To provide support for our in silico prediction, we treated CML 
and normal CD34+ cells and LSCs with EZH2i and dasatinib 
(DAS), alone and in combination (Fig. 3B–F; Supplementary 
Fig. S5C–S5E, S6B–S6D). EZH2i selectively targeted the loss 
of H3K27me3 in the presence of DAS (Fig. 3B; Supplementary 
Fig. S5B). Furthermore, combination treatment with DAS and 
EZH2i led to a significant reduction in cell viability, even in the 
undivided “TKI-persistent” cells (Fig. 3C) and was accompanied 
by increased apoptosis (Fig. 3D) and a pronounced reduction 
in CFC and CFC/GEMM outputs compared to DAS treat-
ment alone (Fig. 3E). Furthermore, combined EZH2i and DAS 
treatments reduced LTC-IC outputs to 1% of those of no drug 
controls (Supplementary Fig. S5E), and the effects of EZH2i 
in the presence of DAS were more than additive (Fig. 3F). DAS 
treatment similarly reduced cell viability and the CFC potential 
of cells in which EZH2 was knocked down by shRNAs (Fig. 3G).
To determine the effect treatment would have on LSCs 
within a bone marrow microenvironment, human CD34+ 
cells were engrafted into NOD/SCID gamma (NSG) mice for 
10 to 13 weeks and then treated in vivo with nilotinib (NIL) 
figure 2.  CML cells are sensitive to chemical and genetic inhibition of EZH2. A, schematic for EZH2i treatment in primary CML and normal CD34+ 
cells; n = 3 bioreplicates in all instances described below. B, representative Western blot analysis of H3K27me3 and H3K27me1 levels in CML and normal 
CD34+ cells treated for 6 days with increasing concentrations of EZH2i as indicated. L, laemmli buffer; total cellular protein. A, acid extraction; enriched 
for histones. Levels of bulk histone H3 were used as loading controls. C, viability of CML and normal CD34+ cells treated with EZH2i for 6 days. Mean total 
viable cell counts (top); mean viable undivided (CTVmax) CD34+ cells (bottom). NDC, no drug control. D, levels of apoptosis (Annexin V–positive cells) in CML 
and normal CD34+ cells treated with EZH2i. Mean total apoptosis (top) and mean apoptosis in undivided (CTVmax) CD34+ cells (bottom). E, colonogenic 
(CFC) potential of CML and normal CD34+ cells treated with EZH2i. Mean total CFC outputs (top) and GEMM outputs (bottom) from CD34+ cells; total CFC 
outputs from LSCs (CD34+CD38−; bottom). F, colonogenic potential of CML and normal CD34+ cells from LTC-IC after 3- or 6-day treatment with EZH2i. The 
percentage of cells Ph+ (i.e., BCR–ABL+) in NDC (day 6) is shown by the arrow (red). G, effect of EZH2 shRNA knockdown in CML CD34+ cells. Cell counts (left), 
CFC output (middle), and apoptosis (Annexin V–positive cells; right) for CML CD34+ cells transduced with EZH2 or control shRNA for 3 days. Two different 
EZH2 shRNAs were used to derive data. H, scatter plot depicting global mRNA expression changes (z-scores) for 975 and 1,473 genes in CML and normal 
CD34+ cells, respectively, as a consequence of EZH2i treatment (and where both mRNA and H3K27me3 status is known; E-MTAB-2893 and E-MTAB-3552). 
H3K27me3 targets (>±1 SD from the mean) are highlighted (red). Significant P values (*; one-sample t tests in C–G) are shown in the key below G. EZH2i is 
GSK343 for data shown in B–F and in H. I, Venn diagrams depict the degree of overlap between genes showing mRNA changes due to EZH2i treatment in CML 
and normal CD34+ cells; all genes (top), H3K27me3 target genes (bottom). The percentage of overlap with respect to totals for CML CD34+ cells (left).
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figure 3.  Both TKI and EZH2i upregulate H3K27me3 targets, and combined treatment potentiates loss of LSCs. A, summary of global mean mRNA 
expression changes found in LSCs after treatment with TKI for 7 days in vitro based on Affymetrix analysis (E-MTAB-2594). Percentages of genes 
upregulated or downregulated are shown for H3K27me3 targets and other genes for each TKI treatment (n = 6 bioreplicates in all cases). Total number 
of mRNAs affected is shown along the bottom. B, representative Western blot analysis (L, laemmli buffer) of H3K27me3 and H3K27me1 levels in CML 
CD34+ treated with DAS with and without increasing concentrations of EZH2i (GSK343). C, viability of CML CD34+ cells treated with EZH2i and DAS for 
6 days. Mean total viable cell counts (left) and mean viable undivided (CTVmax) CD34+ cells (right). D, levels of apoptosis (Annexin V–positive cells) in CML 
CD34+ cells treated with EZH2i and DAS for 6 days. Mean total apoptosis (left) and mean apoptosis in undivided (CTVmax) CD34+ cells (right). E, colono-
genic (CFC) potential of CML cells treated with EZH2i and DAS for 6 days. Mean total CFC outputs (left) and GEMM outputs (middle) from CML CD34+ 
cells and total CFC outputs from LSCs (CD34+CD38−; right). F, colonogenic potential of CML CD34+ cells from LTC-IC following 3- or 6-day treatment with 
EZH2i and DAS (same samples as shown in E). Expected levels (green dotted line) are based on efficacy of EZH2i alone on CD34+ cells (from F). G, cell 
counts (left) and CFC output (right) for CML CD34+ cells transduced with EZH2 or control shRNA for 4 days in the presence of DAS. Two different EZH2 
shRNAs were used to derive data. Results in C–G are shown as a percentage change from treatment with DAS (150 nmol/L) only, unless indicated. n = 3 
bioreplicates in C, D, E, F; n = 4 bioreplicates in G. H, schematic showing the experimental design for EZH2i and TKI treatment of NSG mice engrafted with 
CML CD34+ samples. I, representative FACS scatter plots showing the proportions (%) of human CML CD45+ cells staining positive for CD34+ (hCD34+) 
in bone marrow from NSG xenografts following in vivo treatment with EZH2i (EPZ-6438) or TKI (NIL, nilotinib) alone and in combination for 25 days. SSC, 
side scatter. J (left), mean absolute number (top) and mean % (bottom) of Ph+ hCD45+ cells from bone marrow of NSG xenografts treated with vehicle 
(NDC), EZH2i, NIL, and EZH2i + NIL (25-day treatment; n = 2 CML CD34+ samples; n = 8 mice per arm). Right, mean absolute number (top) and mean % 
(bottom) Ph+ hCD45+CD34+ cells from the same experiments. K, mean absolute number (top) and mean % (bottom) of Ph+ hCD45+CD34+CD38− cells from 
the bone marrow of NSG xenografts treated as above (n = 1 CML CD34+ sample; n = 3–4 mice per arm). In J, K, % Ph+ cells are expressed as a percentage of 
hCD45+ in NDC. Significant P values (*; one sample t tests in C–G; Student t tests in bar diagrams of J, K) are as shown in the key next to K.
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and an EZH2i (EPZ-6438; ref. 20) singly and in combination 
for either 14 or 25 days (Fig. 3H). After 14 days of treat-
ment, we observed significant reductions in levels of leukemic 
(Ph+) human CD45+ cells, CD45+CD34+ progenitor cells, and 
primitive CD45+CD34+CD38− stem cells in the bone marrow 
of mice treated with both NIL and EZH2i compared to NIL 
treatment alone (Supplementary Fig. S13A–S13D). Impor-
tantly, after 25 days of treatment, we observed near-complete 
elimination of CD45+CD34+ progenitor cells (Fig. 3I and J; 
Supplementary Fig. S13E and S13F) and greater than a 70% 
reduction of CD45+CD34+CD38− cells (Fig. 3K) in combined 
NIL/EZH2i treatment compared to NIL alone. Again, the 
effects of EZH2i on CML stem and progenitor cells in the 
presence of NIL appeared more than additive in vivo and 
mirrored our in vitro findings. These results taken together 
demonstrate a clear rationale for combining TKI treatment 
with EZH2i, given the efficacy of an EZH2i at targeting primi-
tive CML cells not eradicated by TKI alone.
As TKI-persistent cells are refractory to apoptosis (6, 7), we 
examined the mechanism of action of combined DAS plus 
EZH2i on the mRNA expression of a set of genes, including 
14 H3K27me3 targets from apoptotic pathways (Fig. 4A). 
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figure 4.  Molecular analysis of the effects of EZH2i and TKI on apoptotic pathways in CML CD34+ cells. A, main panel, heat maps showing mean fold 
changes in the mRNA expression (Fluidigm) of a number of apoptotic pathway genes following treatment of CML CD34+ samples with EZH2i (1,000 
nmol/L) or DAS (150 nmol/L) alone or in combination (n = 4 bioreplicates assayed in triplicate); mean changes in mRNA expression of specific p53 path-
way genes and BCL6 are shown (right). B, bar diagrams showing comparisons of predicted (from individual treatments using an additive model; gray) and 
actual changes in mean mRNA expression levels of H3K27me3 (blue; left) and other targets (pink; right) following treatment with both EZH2i and DAS in 
each bioreplicate CML sample (n = 4) shown in A. Error bars are SEMs in all instances. Significant P values (*; one-sample t tests in A, Student t tests in 
bar diagrams of B) are as shown in the key next to B. C, representative Western analysis (laemmli buffer) of p53 levels in two CML CD34+ samples before 
and after EZH2i ± DAS treatment. D, schematic of a putative interactome map between EZH2/H3K27me3 (blue), BCL6 (red), and p53 (purple) targets 
which mediate cell-cycle arrest and apoptosis in CML CD34+ cells. BCL6 targets were obtained from previously published data (22). BCL6 is self-regula-
tory as shown. Cell-cycle inhibitors and activators are shown in orange and green, respectively.
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BCL6, an H3K27me3 target and a known repressor of TP53 
and CDKN2A (p16/ARF) in TKI-persistent cells (21, 22), was 
upregulated by combined DAS plus EZH2i treatment. None-
theless, there was a significant upregulation of apoptotic 
genes, including TP53 transcriptional targets (e.g., CDKN1A, 
BAX, BBC3, NOXA, and TNFRS10B), and an enhanced activa-
tion of H3K27me3 targets, including CDKN2A, compared to 
DAS or EZH2i treatments alone. In keeping with our pheno-
typic data, the enhanced activation of H3K27me3 targets and 
apoptotic genes exceeded predicted levels based on additive 
effects (Fig. 4B). Furthermore, we confirmed increased levels 
of the p53 protein in CML CD34+ cells treated with EZH2i 
and in combination with DAS (Fig. 4C). We generated a con-
nectivity map between targets of EZH2 (H3K27me3), BCL6, 
and p53 in the apoptosis pathway (Fig. 4D) and propose that 
EZH2 inhibition, when potentiated by TKI, could engage 
apoptosis downstream of p53 through reactivation of proa-
poptotic targets (e.g., BBC3 and BIM), and/or by directly 
rescuing p53-mediated apoptosis by overcoming BCL6- and 
EZH2-mediated repression upstream of p53.
DiscUssiON
Due to increased patient survival, CML will become the most 
prevalent form of leukemia in the next 20 to 30 years (23), with 
TKI-persistent LSCs remaining a significant unmet clinical 
need for the majority of these patients. Because TKIs are highly 
effective against the bulk of leukemic cells and are generally well 
tolerated by most patients with CP CML, new therapies that 
target LSCs must be effective and safe when combined with 
TKI. Our preclinical results, derived from more than 40 primary 
samples, and hypothesis-driven by global analyses, demonstrate 
that inhibition of EZH2 in combination with TKI is comparable 
to, if not more effective than, other novel strategies for target-
ing CML LSCs (Supplementary Table S4), none of which have 
reached the clinic to supplement or replace TKI as the stand-
ard of care. Given that EZH2 can have tumor-suppressor or 
oncogenic roles, further investigations are required to optimize 
preclinical therapeutic strategies and to identify biomarkers of 
EZH2 and H3K27me3 inhibition in CML cells. Nonetheless, 
novel, orally administered EZH2 inhibitors currently in trials 
are showing low toxicity, significant reductions of H3K27me3 
levels at clinically achievable doses, and promising objective 
responses across a range of tumor types. These early trial data, 
taken together with our results and those of Xie and colleagues 
(24), point to a promising new avenue for the development of 
the first epigenetic therapy for the treatment of CML.
MethODs
Primary Samples
Primary CML samples (Ph+ in >90% of CD34+ cells) from patients 
with CP CML were obtained at point of diagnosis prior to TKI treat-
ment (n = 32 bioreplicates in total, for experiments described in this 
article). Normal (i.e., non-CML) control primary samples were obtained 
by granulocyte-colony stimulating factor (G-CSF) mobilization from 
individuals negative for bone marrow involvement upon lymphoma 
staging or from normal cadaveric bone marrow (BM) samples (nor-
mal controls; n = 12 bioreplicates). In all instances, ethical permis-
sion was with written informed consent (West of Scotland Research 
Ethics Service; REC Ref 10/S0704/2 and REC Ref 15/WS/0077). 
See also Supplementary Table S5. Primary CML samples were ran-
domly chosen for the experiments described below and in the text 
without prior knowledge of clinical outcome or response to TKI. The 
investigators were not blinded to the experimental conditions when 
assessing the outcomes, and no datasets were excluded from analysis 
(for all in vitro assays). Experiments on live vertebrates (NSG mice) 
were performed as described below.
Primary samples were stored frozen as mononuclear cells (MNC) 
isolated by density gradient centrifugation or as CD34+ cells isolated 
using CliniMACS (Miltenyi Biotech). After thawing, CML cells were 
recovered by culturing in physiologic growth factors (SCF 0.2 ng/mL, 
G-CSF 1 ng/mL, GM-CSF 0.2 ng/mL, IL6 1 ng/mL, LIF 0.05 ng/mL, 
MIPα 0.2 ng/mL; StemCell Technologies), whereas normal control 
stem cells were cultured in 5 growth factors (SCF 100 ng/mL, G-CSF 
20 ng/mL, IL3 20 ng/mL, IL6 20 ng/mL, FLT3 100 ng/mL). For 
isolation of HSC/LSC (CD34+CD38−) and HPC/LPC (CD34+CD38+), 
MNCs or CD34+ cells were stained with CD34-APC, CD38-FITC, 
or CD38-PerCP-Cy 5.5 antibodies (555824, 555259, and 551400, 
respectively; BD Biosciences), before being subject to FACS to obtain 
the appropriate populations using a FACS Aria cell sorter (Beckton 
Dickinson).
Cell Culturing
For experiments involving GSK343, CML and normal primary cells 
were cultured as above for the treatment regimens described below 
and in the text with media change every 3 days. For experiments 
involving treatment of LSCs with TKIs [imatinib (IM)/5 μmol/L, dasat-
inib (DAS)/150 nmol/L, and nilotinib (NIL)/5 μmol/L; Bristol-Myers 
Squibb and Selleckchem] for up to 7 days, cells were grown in serum-
free media without growth factors. The KCL22 cell line (CML, blast 
crisis; obtained from DSMZ cell bank in 2014; Mycoplasma negative; 
authenticated by DSMZ using RT-PCR for BCR–ABL1 expression and 
microsatellite repeat typing) was grown in RPMI-1640 (Sigma) sup-
plemented with 10% fetal bovine serum, 2 mmol/L l-glutamine, and 1% 
penicillin–streptomycin. Experiments involving KCL22 cells were per-
formed within 6 months from the date cells were obtained from DSMZ.
Proliferation, Differentiation, Apoptosis, and  
Colony-Forming Cell Assays for EZH2 Inhibition  
with GSK343, GSK126, and EPZ-6438
Primary cells from patients with CML and normal controls (n = 3 
each; CD34+, CD34+CD38−, or CD34+CD38+) were cultured as above for 
6 days with or without EZH2 inhibitors and/or DAS (50–150 nmol/L), 
with media and drug change every 3 days. Viable cell numbers (trypan 
blue exclusion) in culture were measured every 3 days, and fold 
change was determined relative to input. To monitor proliferation/
cell division, cells were labeled with cell trace violet (CTV; Invitrogen). 
Following culture, the cells were costained with CD34-APC to assess 
differentiation status and loss of CD34+. CTV and CD34 levels were 
analyzed by flow cytometry and the percentage recovery of input for 
CD34+ cells in each cell division was determined. Colcemid treatment 
was used to determine gating for undivided cells. To assess levels of 
apoptosis, cells were incubated with Annexin V–FITC and 7-AAD 
(556419 and 559925, respectively; BD Biosciences) and analyzed 
by flow cytometry. Apoptotic cells were defined as Annexin V and 
Annexin V–7AAD positive. For CFC assays, cells cultured with or 
without GSK343 ± DAS for 6 days were plated in methylcellulose 
(MethoCult; StemCell Technologies) and the number and morphol-
ogy of colonies determined after 12 days. Statistical analysis of dif-
ferences in proliferation, CFC counts, and apoptosis was performed 
using one sample t-tests.
LTC-IC Assays for EZH2 Inhibition with GSK343
Primary CD34+ cells from patients with CML and normal controls 
(n = 4 bioreplicates for CML; n = 3 bioreplicates for normal) were 
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cultured as above for 3 or 6 days with or without GSK343 (1,000 
nmol/L) and DAS (150 nmol/L). M2-10B4 and SL/SL fibroblasts 
were established as feeder layers and then irradiated at 80 Gy. Cells 
(5 × 104) were then placed in LTC-IC on irradiated feeders in MyeloCult 
(StemCell Technologies) and maintained for 5 weeks in duplicate 
in the absence of drugs. Cells were then transferred to CFC assays 
in duplicate, maintained in culture for 12 days, and then scored 
as above.
Immunodeficient Murine Xenograft Experiments
CML CD34+ cells were transplanted (1 × 106 cells per mouse) via 
tail-vein injection into female 8-to-12-week-old sublethally irradiated 
(2.25 Gy) NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; The Jackson 
Laboratory). Human cell engraftment was monitored at 8 to 12 weeks 
after transplantation by FACS for the presence of human CD45+ cells 
in the blood. Mice that showed evidence of human cell engraftment 
were randomized and treated with vehicle/no drug control (10% 
N-methyl-2-pyrrolidinone in PEG300), a clinical grade EZH2i (EPZ-
6438; Medkoo Biosciences), nilotinib (LC Laboratories), or a combi-
nation of EPZ-6438 and nilotinib for 14 or 25 days, commencing at 10 
to 13 weeks after transplantation. Drugs or vehicle were administered 
once daily by oral gavage at a dose of 300 mg/kg for EPZ-6438 and 
50 mg/kg for nilotinib. Mice were euthanized at the end of treat-
ments, and marrow contents of ilia, femurs, and tibia were obtained. 
The presence of human CD45, CD34, and CD38 on engrafted cells 
was assessed by FACS. Engraftment data were obtained from n = 3 
(14-day treatment) or n = 2 (25-day treatment) CML CD34+ samples 
derived from different patients. The investigators were blinded to 
the experimental conditions when assessing the outcomes, and no 
datasets or animals were excluded from analysis. Mice were handled 
humanely in accordance with regulations under Home Office License 
PPL 60/4492.
FISH
Colonies from LTC-IC colonogenic outputs and human CD45+ 
or CD45+CD34+ cells from NSG xenografts were scored for the pres-
ence of the Philadelphia chromosome (Ph+). FISH was performed 
with the LS1 BCR–ABL Dual Color, Dual Fusion translocation probe 
according to the manufacturer’s instructions (Abbott Diagnostics). 
For each LTC-IC, nuclei from at least 10 colonies were scored where 
possible. Two hundred nuclei were scored from bone marrow from 
each xenograft.
EZH2 Knockdown
EZH2 shRNAs were subcloned from the pLKO.1 puro vector 
(Sigma Mission shRNA collection) into the NdeI and SpeI sites of 
the pLKO.1 GFP vector. Sequences for EZH2 shRNA 1 and 3 are 
CCGGGCTAGGTTAATTGGGACCAAACTCGAGTTTGGTCCC 
AATTAACCT AGCTTTTTG and CCGGGCTAGGTTAATTGGGACC 
AAACTCGAGTTTGGT CCCAATTAACCTAGCTTTTTG, respectively. 
A scrambled, nontargeting shRNA was used as a control. Ten micro-
grams of each shRNA was transfected into 293T human embry-
onic kidney (HEK) cells along with 6.5 μg HIV1 and 3 μg VSV-G 
constructs. After 24 hours, the medium was replaced with DMEM 
containing 20% serum. KCL22 cells or CML CD34+ cells were trans-
duced in 2 consecutive rounds of 24 and 48 hours with lentiviral 
supernatant supplemented with Transdux (Systems Biosciences). 
Transduction efficiency (% GFP+ cells) was measured by flow cytom-
etry. GFP-positive cells were isolated by FACS using a FACS Aria cell 
sorter and knockdown assessed at the mRNA and protein level.
Western Blotting
Total cellular protein was extracted from primary CML and nor-
mal samples by direct lysis in laemmli buffer or by acid extrac-
tion. Cell lysates were then run out on 4% to 12% SDS-PAGE gels, 
transferred to PVDF membrane and probed with the appropriate 
antibodies. Antibodies used were for H3K27me3 and H3K27me1 (see 
ChIP-seq section below), histone H3 (9715; New England Biolabs), 
EZH2 (5246; New England Biolabs) and p53 (sc-126; Santa Cruz 
Biotechnology). Validation of specificities of, and citations for, these 
antibodies can be found on the manufacturers’ websites.
Experimental Analysis by Affymetrix GeneChips, TaqMan 
Low-Density Array Cards, and Fluidigm
mRNA was extracted using the RNeasy Mini Kit (Qiagen) and 
DNase I treated on columns using the ribonuclease (RNase)-Free 
DNase Set (Qiagen). Purity was determined by the Agilent Bio-
analyzer and Agilent RNA 6000 Nano Kit (Agilent Technologies). 
Affymetrix GeneChIP analysis (using HuGene-1_0-st-v1 arrays) was 
performed using 50 ng of total RNA as starting material according 
to the manufacturer’s instructions. For qPCR, cDNA was obtained 
using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems) or, 
alternatively, 300 cells were sorted and processed with the CellsDirect 
One-Step qRT-PCR Kit (Invitrogen). Real-time qPCR was carried out 
using FAM-MGB probes for the genes of interest on the TaqMan 
Low-Density Array (ABI7900; Applied Biosystems) and Fluidigm 
48.48 Dynamic Array Integrated Fluidic Circuit platforms (Fluidigm 
Corporation). Validation of mRNA expression changes determined by 
Affymetrix GeneChip analysis is shown in Supplementary Fig. S14A–
S14E. All oligonucleotide primer pairs are available upon request.
Computational Analysis of Affymetrix GeneChips
Affymetrix datasets were processed using one of two different 
approaches. For CD34+CD38− and CD34+CD38+ normal and CML 
datasets generated for this study (E-MTAB-2581, Affymetrix HuGe 
1.0 ST) or for datasets generated from treatment of CML or nor-
mal CD34+ with GSK343 (E-MTAB-2893, E-MTAB-3552, Affymetrix 
HuGe 1.0 ST), Bioconductor was used for data preprocessing (affy 
and aroma.affymetrix packages), quality control (simpleaffy package), 
differential gene expression analysis (limma package), and gene anno-
tation (annotate package). Datasets for CML CD34+ cells treated with 
IM in vivo (GSE12211, Affymetrix Human Genome U133A 2.0) were 
normalized using RMA (affy v1.42.3). Datasets from LSCs treated 
with DAS, IM, and NIL (E-MTAB-2594, Affymetrix HuGe 1.0 ST) 
generated for this study were normalized using RMA (oligo v1.28.2) 
and subsequently merged and batch-corrected using COMBAT 
(inSilicoDb v2.0.1, inSilicoMerging v1.8.6). For pathway analysis, dif-
ferentially expressed genes from E-MTAB-2893 and E-MTAB-3552 
were analyzed for enrichment of Panther Pathways using the DAVID 
Bioinformatics Database. See also Supplementary Table S3.
ChIP-seq
H3K4me3 (Abcam, ab8580), H3K27me3 (Millipore, 07-449), and 
H3K27me1 (Millipore, 07-448) ChIPs were performed (validated 
for specificity as previously described in ref. 25) using between 104 
and 106 primary HSCs (CD34+CD38−), LSCs (CD34+CD38−), or 
LPCs (CD34+CD38+) as starting material with no preclearing of 
chromatin (n = 3 for all cell types). The three CML samples used 
for ChIP-seq displayed typical patterns of PRC2 misregulation 
(Supplementary Fig. S15A–S15C). ChIP-seq libraries (see Supple-
mentary Table S6) were prepared according to the manufacturer’s 
protocols (Illumina). HSC, LSC, and LPC ChIP-seq was performed 
in singlicate per bioreplicate, and the read data obtained were 
deposited into the European Nucleotide Archive (Access. No. 
PRJEB8291).
Reads obtained from ChIP-seq were aligned to the human genome 
(hg18; NCBI build 36.1), and uniquely mapped reads were extended to 
150 bp and processed as BED or bigWig files for further analysis and 
visualization in the UCSC genome browser. H3K27me3 read densi-
ties (per 106 reads) at each of 33,626 gene promoters were determined 
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for each CML and normal sample across 2-kb windows flanking the 
transcriptional start site (TSS; 1 kb up- and downstream of the TSS). 
These read densities were quantile normalized to reduce bias, and only 
promoters where all three samples gave read densities greater than 
0 at a given promoter were used for further data mining. As a result, 
read densities for 26,760 promoters (H3K27me3) or 24,292 promoters 
(H3K27me1) were used for the analyses described in the text.
Bona fide H3K27me3 target genes were defined as follows. k-means 
clustering of ChIP-seq read densities/106 reads at a resolution of 
50 bp across 5 kb at each of 33,626 promoters (2.5 kb up- and down-
stream of the TSS) was performed by seqMINER (26). Clusters were 
generated that defined promoters having (i) H3K4me3 only, (ii) both 
H3K4me3 and H3K27me3, or (iii) neither histone modification (Sup-
plementary Fig. S16A and S16B). Membership of gene promoters in 
these three classifications was validated by ChIP qPCR (Supplemen-
tary Fig. S17A–S17C) using SYBR-Green Master (Rox, Roche) in a 
Stratagene Mx3000P qPCR system (Agilent Technologies). Oligonu-
cleotide primer pairs are available upon request.
Promoters defined as “H3K4me3 only” or having “neither” histone 
modification were then used as a measure of background noise for 
H3K27me3 in ChIP-seq datasets derived from each patient or normal 
sample. On a per-sample basis, those promoters with H3K27me3 
read densities (across 2-kb promoter windows) that were 3 standard 
deviations above background noise were considered as H3K27me3 
targets. In this way, each H3K27me3 ChIP-seq dataset had a uniquely 
defined measure of background (i.e., a threshold), above which bona 
fide H3K27me3 targets could be identified.
Statistically significant changes in H3K27me3 read densities at 
promoters of H3K27me3 target genes (defined as above) were deter-
mined using either Student t tests or one-sample t tests as appropri-
ate. Significance was determined at the level of individual promoters. 
In addition, promoters shown to be statistically significant were also 
required to have at least 1.5-fold changes in H3K27me3 levels to be 
considered as promoters with obvious changes. Promoters ranked as 
having H3K27me1 levels in the top 25% of all promoters genome-
wide were used for the analysis described in Supplementary Fig. 
S8A and S8B. Yates χ2 or Fisher exact tests were used to determine 
statistically significant differences between observed and expected 
frequencies of changes in H3K27me3 at promoters (gains or losses) 
with respect to changes in mRNA expression. Expected frequencies 
were the number of promoters showing gains or losses in H3K27me3 
due to global H3K27me3 reprogramming on a per sample basis, or 
for common H3K27me3 reprogrammed genes. Observed frequencies 
were the data shown in Supplementary Fig. S4B and S4C. Heat maps 
of common H3K27me3 reprogrammed genes (Supplementary Fig. 
S3B) were generated using Cluster 3.0 (27).
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